When neuroscientist Christopher Walsh and his team at Boston Children's Hospital sequenced the genomes of brain tissue from people with Alzheimer's disease, they expected to find the usual suspects: variants linked to amyloid plaques, tau tangles, maybe some inflammation-related genes. What they found instead was unexpected enough to make even seasoned researchers pause.
"We've seen these exact mutations in blood cancers like lymphoma and leukemia," Walsh said in a statement. "To some extent, Alzheimer's disease is a little like cancer , driven by the same mutations."
The finding, published in Cell on April 21, 2026, is the result of an ambitious genetic survey: deep sequencing of 149 cancer-driving genes across 311 brain samples from 190 people with Alzheimer's and 121 without the condition. The team was looking for somatic mutations, the kind that accumulate silently over a lifetime as cells divide and DNA replication makes small errors. What they found was that Alzheimer's brains carried more of these single-letter DNA changes than healthy tissue, and they weren't scattered randomly. Instead, the mutations clustered in the same handful of genes, again and again, in person after person. [1]
"That was the really unexpected finding , that there's a totally new mechanism for Alzheimer's disease pathogenesis," said August Yue Huang, a professor at Harvard Medical School and associate member of the Broad Institute, who co-led the work. [2]
The Immune Cells Gaining Unwanted Mutations
The cells in question are microglia, the brain's resident immune cells. Think of them as the brain's dedicated cleanup crew: they sweep up debris, clear out dead or infected cells, and keep the neural environment running smoothly. In Alzheimer's disease, these cells become chronically activated, fueling neuroinflammation that damages nearby neurons. [3]
When the researchers looked closely at brain tissue from people with Alzheimer's, they found that microglia-like brain macrophages , cells that behave like microglia but may originate from outside the brain , carried mutations in cancer driver genes. Specifically, the mutations kept appearing in genes associated with clonal hematopoiesis, a condition where blood stem cells accumulate mutations that allow their descendants to proliferate unchecked. The genes TET2, ASXL1, and DNMT3A turned up most frequently. [1]
Clonal hematopoiesis has been linked to blood cancers for years, but recent research has suggested its reach extends further. People with these mutations have a higher risk of cardiovascular disease, for instance, and now possibly neurodegenerative disease as well. The connection makes biological sense: these genes regulate how DNA is packaged and expressed. When they malfunction, cells can become chronically inflamed and prone to abnormal growth. [5]
The team went a step further and tested these mutations directly. Using iPSC-derived microglia-like cells engineered to carry TET2, ASXL1, and DNMT3A variants, they watched the cells develop the same inflammatory and proliferative signatures seen in actual Alzheimer's brains. The mutations weren't just present , they were actively driving the cellular behavior characteristic of the disease. [1]
Where the Mutations Come From
One of the most striking aspects of the study was a finding the researchers didn't initially expect. When they examined paired blood samples from the same patients, they discovered the same cancer driver mutations present in the blood. That shared genetic signature suggests these mutated immune cells originate in the bone marrow and travel to the brain, rather than arising spontaneously within the central nervous system. [2]
The likely explanation involves the blood-brain barrier, a protective membrane that normally keeps circulating immune cells out of the brain. As the body ages, or following injury or illness, this barrier becomes leakier. Blood immune cells slip through, settle into brain tissue, and take on the characteristics of microglia-like cells. Cells carrying clonal hematopoiesis mutations appear to have a survival advantage in this new environment: they proliferate more readily and respond more aggressively to triggers like amyloid or tau proteins. [4]
"The mutant cells dominate the brain environment and create a more inflammatory and hostile environment, causing bystander neurons to die off," Huang explained. [2]
This matters because it reframes a piece of Alzheimer's pathology that didn't quite fit before. Researchers had long known that neuroinflammation plays a critical role in the disease, but the source of that inflammation wasn't fully clear. These findings suggest that for some people, the inflammatory immune cells causing damage may literally be foreign invaders , blood cells that settled in the brain and gained mutations that made them more destructive.
A follow-up preprint by Huang and Lee, posted on bioRxiv in May 2025, added another layer: cancer driver mutations detected in blood samples increased Alzheimer's risk independently of APOE4, the most significant known genetic risk factor for the disease. [8] That means people can carry this mutation-based risk even without the APOE4 variant, potentially opening a new pathway for risk assessment.
Why This Changes the Treatment Conversation
The implications for treatment are perhaps the most hopeful part of this research. If Alzheimer's is, in part, driven by the same mutations that fuel blood cancers, then drugs already approved to treat those cancers might be worth investigating. BCL-2 inhibitors, IDH inhibitors, and hypomethylating agents that target TET2, ASXL1, or DNMT3A are all candidates for repurposing. [1][3]
"We have a lot of drugs to fight cancer, and some of them might be useful therapeutically," Walsh said. [2]
It's a compelling idea, though researchers are quick to note that the path from lab discovery to clinical treatment is long. No clinical trials for Alzheimer's using these approaches have yet been announced, and the study establishes association, not direct causation. Other factors beyond these mutations almost certainly contribute to Alzheimer's risk and progression. [6]
Still, the findings open a genuinely new avenue. Most current Alzheimer's research focuses on amyloid plaques and tau tangles, and while those remain important, this work suggests that targeting the immune microenvironment could be equally valuable. The concept of complementing amyloid-targeting therapies with approaches that address microglial dysfunction is gaining traction. [1][7]
There's also potential for earlier identification of at-risk individuals. Because these mutations show up in blood, a simple genetic screen could potentially flag people carrying clonal hematopoiesis variants before symptoms appear. [2] Right now, this kind of screening isn't available clinically, but the research points toward a future where a routine blood test might give people and their doctors more information about neurodegenerative risk.
What This Means Going Forward
Alzheimer's disease is increasingly understood as a condition with multiple contributing pathways , amyloid buildup, tau pathology, metabolic dysfunction, vascular issues, and now possibly mutated immune cells converging over decades. No single drug is likely to address all of these, which is why understanding each piece matters.
This study doesn't overturn what we know about Alzheimer's risk factors like age, genetics, and lifestyle. But it adds a significant new dimension: the possibility that for some people, the disease has roots in mutations that accumulate quietly in immune cells, changing how those cells behave and eventually creating an environment toxic to neurons.
More research is needed to understand how common these mutations are across different populations, whether the mutations directly cause disease or are primarily drivers of progression, and which existing cancer drugs might actually help. Those questions will take years to answer. But for a field that's been searching for new angles on a devastating disease, this study offers one that genuinely surprised the researchers who found it.